BioMarin Pharmaceuticals BMRN Business Segments — S&M expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's business segments — s&m expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's business segments — S&M expenses?
- BioMarin Pharmaceuticals (BMRN) reported business segments — S&M expenses of $124.93M in Q1 2026.
- How has BioMarin Pharmaceuticals's business segments — S&M expenses changed year-over-year?
- BioMarin Pharmaceuticals's business segments — S&M expenses increased by 21.8% year-over-year, from $102.53M to $124.93M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — S&M expenses?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — S&M expenses has grown at a 5.6% compound annual growth rate (CAGR), from $450.35M to $530.16M.
- What does business segments — S&M expenses mean?
- The total spending on sales and marketing efforts to promote the segment's products.
- How do you interpret business segments — S&M expenses?
- Higher spending may signal a product launch or aggressive market expansion, while lower spending could indicate a shift toward operational efficiency or a mature product lifecycle.
- How does business segments — S&M expenses compare across companies?
- Comparable to selling, general, and administrative (SG&A) sub-components at other biotech companies.